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Summary 
We e mployed a newly developed rat model of severe pulmonary hyperten-
sion (PH ) to study if treatment with apolipoprotein (apo)- mimeti c peptide, D-
4F, mitigates PH and re lated pathology. Sprague-Dawley rats underwent sur-
gery to partia ll y li gate their left pulmonary artery, after 3-days they were 
injected with monocrotaline (MeT) and then randoml y se lected to receive a 
daily injec ti on of D-4F or sa line. After 2 1-days of treatment the ani mals were 
examined with respect to iso lated lung hemodynamic measurements and X-
ray microfoca l angiography. T here was no significant difference in ri ght-to-
left heart weight , change in body weight , pulmonary vascu lar resis tance (PVR), 
or pulmonary micro-vascular density between D-4F and saline treated ralS. 
Introduction 
Pulmonary hypertension results in remodeling of large and small pulmo-
nary vesse ls, a disturbance in the delicate balance of venti lation/perfusion, 
and increased load on the right heart. In late slages of the disease, severe PH 
is accompanied by plexiform and neoi ntimal les ions which signifi cantl y in-
crease pu lmonary vascular res istance I. '. A we ll accepted rat mode l of PH 
in vo lves a si ngle subcutaneous injection of MeT, however, thi s model does 
not resu It in neointimal lesions. T herefore, we have developed a rat model of 
severe PH that combines partia l li ga tion of the left pulmonary art ery w ilh 
MeT injection resulting in the formation of neointimal lesions wh ich more 
close ly mimics severe PH in human" The model is inherently useful for 
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investigating possible anti-remodeling treatments aimed at reducing cellul ar 
pro liferation and, in turn, lowering pulmonary vascu lar resistance. 
Apolipoprotein (a po) A-I and apoA-I-mimetic peptides hold great promise 
for treatment of atherosclerosis" '. D-4F has been shown to significant ly re-
duce rapidly evolving atherosclerotic lesions , oxidation and innammation; 
and, there is evidence that it has the ability to improve endothelia l function"' 
'. For these reasons, D-4F was thought to be a good candidate for treatment 
of vascular remode ling in this proliferative model, in which histology also 
confirmed marked innammatory infiltrates'. 
Materials and Methods 
All the studies were done under approval of the Zablocki VA Medical 
Center IACUC review board and in compliance with the National Research 
Council's Guide for the Care and Use of Laboratory Animals. Fifteen (15) 
male Sprague-Dawley rats (280-350 gm) underwent a recovery surgery in 
which the rat is anesthetized, intubated, then through thoracotomy the left 
pulmonary artery is isolated, looped with 4-0 suture and reduced such that the 
ou ter vesse l diameter was 0.61 mm. The animals were allowed to recover for 
3-days, then injected with MCT (60 mg/kg, sub-Q), and randomly selected to 
receive an injection of either D-4F (I mg/ kg/day, i.p.) (N=8), or an equal 
vo lume of saline (control C, N=7). Twenty-one (21) days after injections. the 
animals were anesthetized, a cardiac blood sample drawn , the main pulmo-
nary artery and trachea cannulated, and the heart and lungs excised. The right 
ventricle was dissected from the heart and both segments weighed separately 
as a measure of right ventricular hypertrophy. The iso lated intact lung was 
prepared as previously described"" Brieny, the lung was ventilated, rinse of 
blood and perfused with a physiologic sa line so lution . Then the airway pres-
sure held constant at 6 mmHg, the pulmonary vein pressure (Ppv) kept ambi-
ent. and pulmonary arterial (I' PAl pressure measured over a range of now rates 
(Q, 0-40 ml/min). Finally, the perfusate was replaced with a vascular X-ray 
con trast medium and microfocal angiography pelformed. All statistical com-
parisons were peJformed usi ng at-test (Pd"0.02) SigmaStat 3.0 (S PSS , Chi-
cago, IL). 
Results 
There was no significant difference in key structure/function parameters of 
the PH model between the D-4F treated and the control rats. No significant 
change was detected in the right ventricular hypertrophy, as measured by the 
ratio of the weight of the ri g ht ventricle compared to the left ventricle plus 
septum, see Figure I . There was no significant difference in the gain in body 
weight over the 24-day experiment, see Figure 2. Treatment with D-4F did 
not result in a significant decrease in pulmonary vascular resistance, (PPA -
P,,)/Q,()(), where Q ,oo indicates now rate was normalized to body weight at 100 
ml/min/kg, see Figure 3. Microfocal X-ray angiography did not detect any 
difference in the pulmonary microvascular density, which is significantly reduced 
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Figure I . Ratio of the weight of the righl ventricle compared (a {he left ventricle plus seplllm. 
as a measure 0/ right ventricular hypertrophy. 
in MeT models of PH', as shown in Figure 4. Interestingly , 2 of the rats that 
were receiving OAF treatment di ed approximately 17 days into the experi-
ment (none o f the control rats died) and 0 -4F treated rats appeared to have 
more labored breathing and their lungs appeared worse compared to non-
treated PH rats on gross assessment. 
Conclusion 
Treatment with OAF was not shown to mitigate measures of structura l o r 
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Figure 2. Gain in body weight over the 24-days of exper;melll. 
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FiKure 3. Pulmonary vascular resistance at a flow rate oJ 100 mllminlkg. 
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Figure 4. Example high~magnificalion X-ray 011g;08'-01ll,\' of lower /ullg lobe in control Gild 
D-4F Ireared rats. Inrravascular pres,mre is sel to 21 mmHg and airway pressure 6 mml-Ig. 
Scale 011 left image 1001tlll. 
functional injury induced by a model of severe PH. For some animals it may 
have exacerbated this experimenta ll y- induced illness and/or the progress ion 
of the disease model. 0-4F has been shown to be highly effective at improv-
ing endothelial cell function, which may playa role in reducing rapid evolv-
ing vascular les ions and oxidative injury in experimentally-induced athero-
sc le ros is. MeT is known to be an endothelia l cell toxin , however, knowledge 
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of the role and amount o f ox idative stress in the M eT m odel i s limited 'O One 
possibility i s that D -4F may accelerate vascul ar occ lusi ve lesions in thi s model 
of severe PH by protecting endothelial ce lls from apoptotic cell death. D -4F 
may rescue endothelial ce ll s that sloughed off of the vesse l wall , allowing 
them to remain in c ircu lati on lo nger than normal and providing them greater 
opportunity to beco m e trapped in the lung and subsequentl y complicate and 
accelerate vasculopath y in the microvascu lature of this model of PH . Sup-
ported by Department of Veterans Affairs. 
References 
I . JEFFERY, T. K . and WANSTALL, J. c., Pulmonary vascul ar remodeling: a target 
for t.herapeutic intervention in pu lmonary hypertension, Pharmacol Ther, I , 1-20, 
2001. 
2. TUDER, R. M., et aI. , The pat.hobiology of pulmonary hypertension. Endothe-
liUl11, Clin Chest Med, 3, 405- 18, 200 I . 
3. MOLTHEN, R., et aI. , Blood flow modu lati on induces differences in models of 
pultnonary vascular remodeling in the rat , Proceed ings of the American Thoracic 
Society (PATS), A687, 2006. 
4. L1, X., et aI., Differential effects of apol ipoprotein A -I -mimeti c peptide on evolv-
ing and established atherosclerosis in apolipoprotein E-null mice, C irculation, 12, 
170 1-5, 2004. 
5. NA VAB , M ., et aI., Human apolipoprotein A-I and A-I mimetic peptides: poten-
ti al for atherosclerosis reversa l , Curr Opin Lipidol , 6, 645-9, 2004. 
6. SHAH, P. K. , Acu te HDLlApo A I Infusion Therapy for Remodeling/Regression 
of A theroscero lsis: A promising New Treatment Paradigm, Inadian Heart J, 210-
2 16, 2006. 
7. FORRESTER, J. S. and SHAH, P. K ., Emerging strategies for increasing high-
density lipoprotei n, Am j Card iol, I I , 1542-9, 2006. 
8. OU, Z. , et a I. , L-4F, an apo lipoprolein A-I mi'l1etic, restores nitric ox ide and 
supcrox ide anion balance in low-density li poprotein-lreated endothelial cell s, Cir-
culation, I I , 1520-4. 2003. 
9. MOLTHEN, R. c., ct aI., Quantitative models of the rat pulmonary arterial tree 
morphomet.ry appl ied to hypoxia-induced arteri al remodeling, j App l Physiol , 6, 
2372-84; discussion 2354, 2004. 
10. AZIZ, S. M ., et aI. , Oxidative stres mediates monocrotaline-induced alterations 
in tenasc in express ion in pulmonary artery endotheli al cell s, Int j Biochem Cell 
Bioi, 5, 775-87, 1997. 
